Curated News
By: NewsRamp Editorial Staff
October 26, 2026

Oncotelic's AI Platform Identifies Liver Cancer Gene Signature

Discuss on Substack
Original Source

TLDR

  • Oncotelic's PDAOAI platform identified a validated four-gene HCC signature, giving OTLC an edge in AI-driven oncology drug development and trial stratification.
  • PDAOAI's Partitioned Literature Aggregation algorithm combined gene-expression and survival analyses to identify four genes, independently validated in 203 Japanese HCC patients.
  • Oncotelic's AI-driven research may improve liver cancer patient stratification and accelerate development of targeted therapies like Sapu003 for better outcomes.
  • Oncotelic plans to scale PDAOAI to 100 billion biological vectors, and its BIO REBOOT initiative invites researchers to submit projects for funding and support.

Impact - Why it Matters

The identification of a validated four-gene prognostic signature for hepatocellular carcinoma could significantly improve patient stratification in clinical trials, particularly for Sapu003, potentially leading to more personalized and effective treatments for liver cancer. Oncotelic's AI-driven approach, PDAOAI, demonstrates the growing role of artificial intelligence in drug discovery, enabling the rapid generation of testable biological hypotheses from vast datasets. This matters because liver cancer is often diagnosed late and has limited treatment options; better prognostic tools can help match patients to the most appropriate therapies, improving outcomes. Moreover, the BIO REBOOT initiative opens doors for external researchers to leverage Oncotelic's platform, fostering collaboration and accelerating innovation in oncology and immunotherapy. As AI continues to transform biomedical research, Oncotelic's advancements could pave the way for similar breakthroughs in other cancers with unmet needs.

Summary

Oncotelic Therapeutics (OTCQB: OTLC) has announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), a form of liver cancer. Published on October 23, 2026, the study utilized Partitioned Literature Aggregation (PLA), Oncotelic’s patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to pinpoint four genes: FKBP1A, EIF4E, RRAGC, and PPARGC1A. The signature’s association with patient survival was independently validated in a Japanese HCC cohort of 203 patients, reinforcing its potential as a prognostic tool. These findings support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus, which Oncotelic is developing for HCC.

Oncotelic Chief Business Officer Saran Saund presented the research approach during an October 22 keynote at the 22nd Drug Discovery Strategic Summit in California. The company emphasized the potential of partitioned AI investigations to uncover testable biological hypotheses and accelerate drug discovery. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research. Through its BIO REBOOT initiative, the company also invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning, and clinical development, subject to scientific review and available resources.

To view the full press release, visit https://ibn.fm/ctJ4J. Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC. This news was distributed by BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed), and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's AI Platform Identifies Liver Cancer Gene Signature

Blockchain registration record for this content